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Halocyclocarbamation of benzyl N-(1-phenyl-3-butenyl)carbamates afforded 6-functionalized 
4-aryl-1,3-oxazinan-2-ones with moderate to excellent diastereoselectivity depending on the 
N-substituent. Importantly, in contrast to reported cyclocarbamations of homoallylic 
carbamates which are generally trans-diastereoselective, cyclization of N-unsubstituted Cbz-
protected homoallylamines led to cis-1,3-oxazinan-2-ones, predominantly. The use of N-
benzylated and in situ prepared N-silylated derivatives resulted however in trans-selectivity. 
Transition states are proposed to explain the stereochemical influence of the N-substituent on 
the cyclocarbamations. The functionalized 1,3-oxazinan-2-ones could be further elaborated 
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1,3-Oxazinan-2-ones form an important class of heterocyclic compounds which have been 
studied for their biological activities,1 showing antibacterial,2 anti-inflammatory,3 anti-HIV,4 
and antithrombotic activities.5 Furthermore, 1,3-oxazinan-2-ones are useful compounds for 
further synthetic transformations to natural products6 or biologically relevant compounds,7 
and are naturally occurring compounds, e.g. the maytansinoid antitumor compounds.8 The 
closely related 1,3-aminoalcohols, which are suitable precursors of 1,3-oxazinanones,9 as well 
as derived products from the latter heterocycles,10 have found wide application as ligands, 
auxiliaries and phase transfer catalysts in organic chemistry.11
6
 One of the two most important 
methods for the asymmetric synthesis of 1,3-oxazinan-2-ones, next to halocyclocarbamation 
of chiral homoallylic carbamates, a,e-h,10 involves cyclization of chiral 1,3-aminoalcohols.7a,9a-
c,e More specifically, the 3-phenyl-1,3-aminoalcohol moiety is an important C3-unit present in 
naturally occurring products, such as (-)-cytoxazone (1), 12  (-)-codonopsinine (2), 13  the 
lythraceous alkaloids (-)-lasubine I (3), (-)-lasubine II (4),14 and vertine (cryogenine) (5) with 
ataractic, anti-inflammatory, antispasmodic and antimalarial activity. 15 Other examples are 
1,2-diphenyl substituted diphenylpyraline derivatives cis-6 and trans-6 with good 
antimycobacterial activity,16 the vesicular monoamine transporter type 2 (VMAT2) antagonist 
dihydrotetrabenazine (DTBZ) as a potent hypoglycemic agent, 17  and (S)-dapoxetine (7), 
which is used for treatment of premature ejaculation and is structurally related to fluoxetine 
(Prozac) (8).18 Moreover, 3-phenyl-1,3-aminoalcohols are also useful in the synthesis of drug-
like azetidines,19 and piperidines.20 Very recently it was shown that anti-2-alkoxy-3-amino-3-
arylpropan-1-ols and the corresponding ring closed cis-5-alkoxy-4-aryl-1,3-oxazinanes are 
promising new types of antimalarial agents.21
In the present article, the results of an extensive study on the diastereoselective electrophile-
induced cyclocarbamation of different N-protected benzyl N-(1-phenyl-3-butenyl)carbamates 
towards the synthesis of cis- or trans-6-(bromomethyl)-, 6-(iodomethyl)- and 6-
(phenylselenomethyl)-4-phenyl-1,3-oxazinan-2-ones are disclosed. These oxazinan-2-ones 

















































2. Results and discussion 
 
Despite the fact that electrophile-induced cyclocarbamation of homoallylic carbamates to 4,6-
disubstituted 1,3-oxazinan-2-ones has been reported regularly in organic synthesis,6a,d-f,h,10b,22
6
 
the method has not been developed in a general sense. Mostly trans-4,6-disubstituted 
oxazinanones are prepared starting from fully N-substituted homoallylic carbamates without 
the development of a selective preparative method to the cis-diastereomers. a,d,h,10b,22a,b 
Moreover, a lack of diastereoselectivity in some cyclocarbamations detracts from synthetic 
utility.6d,22c,d Benzyl N-(1-phenyl-3-butenyl)carbamates 9 were prepared according to a 
recently described iodine-catalyzed three-component condensation of benzaldehydes, 
benzylcarbamate and allyltrimethylsilane, 23
The benzyl N-(1-phenyl-3-butenyl)carbamates 9 with a free NH group were directly 
submitted to cyclocarbamation with bromine, iodine or phenylselenyl bromide in 
dichloromethane,
 as suitable starting materials for further 
diastereoselective electrophile-induced cyclocarbamation to 6-functionalized cis- and trans-4-
phenyl-1,3-oxazinan-2-ones 10.  
24 furnishing the desired cis- and trans-4-aryl-1,3-oxazinan-2-ones 10a-f in 
79-90% yield after crystallisation with low to good cis-diastereoselectivity (Scheme 1). A 
decreasing cis/trans ratio from 80:20 to 54:46 was observed as the steric demand of the 6-
substituent increases from CH2Br to CH2SePh. Column chromatography on silica gel allowed 
the isolation of the major cis-6-(bromomethyl)- and 6-(iodomethyl)-4-phenyl-1,3-oxazinan-2-
ones 10a-d as diastereomerically pure compounds in acceptable yields (29-42%) together 
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with the pure trans-isomers 10a-d (7-16% yield). This result forms one of the few examples 
in which 4,6-disubstituted 1,3-oxazinan-2-ones resulting from a cis-stereoselective 
halocyclocarbamation have been isolated in a preparatively useful manner. The structural 
assignment of the cis- and trans-isomers 10 is based on analysis of the values of the vicinal 
coupling constants (3JH-H) of H4, H5, H5’ and H6 (Figure 1). The 6-substituent occupies an 
equatorial position both in the cis- and trans-isomers 10 as demonstrated by the typical large 
coupling constants 3JH6-H5 = 9.0 – 11.6 Hz for the axial protons H5 and H6.10b,22a For the cis-
isomers 10, a large coupling constant 3JH4-H5 = 11.3 – 11.6 Hz for H4 and H5 in axial 
positions is also observed. The structure and the stereochemical arrangement of cis-6-
(bromomethyl)-4-(4-methoxyphenyl)-1,3-oxazinan-2-one 10b was unambiguously 
determined by X-ray diffraction analysis (Figure 2). 
 
9a (R1 = H)
9b (R1 = OMe)
1.22 equiv E-X
CH2Cl2, rt, 16 - 24 h







10a (R1 = H, E = Br, 83%, dr cis/trans 75:25)
10b (R1 = OMe, E = Br, 86%, dr cis/trans 80:20)
10c (R1 = H, E = I, 84%, dr cis/trans 74:26)
10d (R1 = OMe, E = I, 90%, dr cis/trans 78:22)
10e (R1 = H, E = SePh, 79%, dr cis/trans 54:46)






































Figure 2. Ortep view of compound cis-10b by X-ray diffraction analysis 
 
Bromocyclocarbamation of homoallylamine 9a with N-bromosuccinimide in dichloromethane 
afforded cis- and trans-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-ones 10a in a good 
cis/trans ratio of 9:1 (Scheme 2). However, the reaction time increased to 48 hours and the 
yield dropped to 74% after extractive work up with 2M aq. NaOH and crystallization from 
dichloromethane and hexane. The latter steps were necessary to convert the unstable 
intermediate 2-benzyloxy-6-(bromomethyl)-4-phenyl-5,6-dihydro-4H-[1,3]oxazines into the 
1,3-oxazinan-2-ones 10a and to remove the formed succinimide and benzyl alcohol. An 
attempted chlorocyclocarbamation of homoallylamine 9b with N-chlorosuccinimide failed, as 
no reaction occurred upon stirring carbamate 9b with 1.22 equiv NCS at room temperature in 










10a (74%, dr cis/trans 9:1) 
Scheme 2. 
 
The diastereoselectivity of the cyclocarbamation of the benzyl N-(1-phenyl-3-
butenyl)carbamates 9 was nicely reversed after in situ protection of the homoallylamines 9 
with a tert-butyldimethylsilyl (TBDMS) group. 6a Treatment of the homoallylamines 9 with 
TBDMS triflate in the presence of 2,6-lutidine in dichloromethane at 0 °C for 2 hours, 
followed by reaction with excess of bromine, iodine or phenylselenyl bromide at 0 °C for 16 – 
 6 
24 hours afforded the cis- and trans-4-aryl-1,3-oxazinan-2-ones 10a-f in 71-76% yield after 
crystallisation with trans-diastereoselectivity (Scheme 3). In the bromocyclocarbamation of 
benzyl N-(1-(4-methoxyphenyl)-3-butenyl)carbamates 9b, the typical excess of 2.44 equiv of 
electrophile was lowered to 2.05 equiv of Br2 to avoid bromination in the ortho-position of 
the aromatic methoxy substituent. The highest trans-diastereoselectivity, up to trans/cis ratio 
9:1, was obtained in the iodocyclocarbamation to 6-(iodomethyl)-4-phenyl-1,3-oxazinan-2-
ones 10c,d. A slight trans-selectivity was observed for the selenides 10e,f. 
 
9a (R1 = H)
9b (R1 = OMe)
1) 3 equiv TBDMSOTf
    4 equiv 2,6-lutidine
    CH2Cl2, 0 °C, 2 h
    
2) 2.05-2.44 equiv E-X
    CH2Cl2, 0 °C, 16 - 24 h







10a (R1 = H, E = Br, 76%, dr cis/trans 24:76)
10b (R1 = OMe, E = Br, 73%, dr cis/trans 30:70)
10c (R1 = H, E = I, 71%, dr cis/trans 10:90)
10d (R1 = OMe, E = I, 75%, dr cis/trans 15:85)
10e (R1 = H, E = SePh, 73%, dr cis/trans 46:54)





Similarly, the N-benzyl-substituted homoallylamines 11, prepared in 65-70% yield by 
protection of homoallylamines 9 with benzyl iodide after deprotonation with NaH in DMF,25
6
 
underwent cyclocarbamation with zero to excellent trans-diastereoselectivity (trans/cis ratio 
from 50:50 to 94:6). a The trans- and cis-4-aryl-3-benzyl-1,3-oxazinan-2-ones 12a-f were 
obtained in 78-86% yield after column chromatography (Scheme 4).  
 
9a (R = R1 = H)
9b (R = H, R1 = OMe)
1.22 equiv E-X
CH2Cl2, rt, 18 - 40 h







12a (R1 = H, E = Br, 86%, dr cis/trans 11:89)
12b (R1 = OMe, E = Br, 85%, dr cis/trans 15:85)
12c (R1 = H, E = I, 85%, dr cis/trans 6:94)
12d (R1 = OMe, E = I, 86%, dr cis/trans 9:91)
12e (R1 = H, E = SePh, 78%, dr cis/trans 33:67)
12f (R1 = OMe, E = SePh, 82%, dr cis/trans 50:50)
R1
R
1) 1.5 equiv NaH
DMF, 0 °C, 30 min
2) 17 equiv BnI
DMF, rt, 10 min
Bn
11a (R = Bn, R1 = H, 70%)




The cis-stereoselectivity of the cyclocarbamation reactions of the N-monosubstituted 
homoallylamines 9 can be explained on the basis of the conformational arrangement in the 
proposed transition state of the reaction (Figure 3).6d The major cis-1,3-oxazinan-2-ones 10 
are probably formed through half-chair type transition state 13 in which both the alkene 
moiety, undergoing the anti-attack of the carbonyl oxygen, as well as the 4-aryl substituent 
adopt pseudoequatorial positions with only minor 1,2-strain between the N-H substituent and 
the neighbouring 4-aryl substituent. The introduction of a second substituent on nitrogen, 
either via in situ N-silylation of carbamates 9 with TBDMSOTf or via N-benzylation to 
carbamates 11, forces the 4-aryl substituent to adopt a pseudoaxial position. In this way the 
1,2-strain with the neighbouring N-TBDMS or N-benzyl substituent is minimized in transition 
state 14 resulting in a small 1,3-diaxial interaction, and the formation of the trans-1,3-




























favored if R = H
14
favored if R = TBDMS or Bn
cis-10 trans-10 or trans-12
R
 
Figure 3. Possible transition states in the formation of the cis- and trans-diastereomers 10 and 12 
 
Having the functionalized 1,3-oxazinan-2-ones 10 in hand, their synthetic potential was 
studied under different conditions. A typical attempt to hydrolyze the 6-(iodomethyl)-1,3-
oxazinan-2-ones 10c,d directly to the corresponding 1,3-aminoalcohols,10a afforded an 
unexpected but interesting new synthesis of 6-arylpiperidine-2,4-diones. Treatment of 4-aryl-
6-(iodomethyl)-1,3-oxazinan-2-ones 10c,d with an aqueous solution of sodium hydroxide 
under reflux in ethanol afforded the 6-arylpiperidine-2,4-diones 15 in 82-86% yield after 
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recrystallisation (Scheme 5). 6-Arylpiperidine-2,4-diones have been prepared as analogues of 
VMAT2 antagonists,26 and represent key intermediates for further synthetic transformations 
to 6-aryl-4-hydroxypiperidin-2-ones, 27  4-hydroxypipecolic acids, 28  (R)-(+)-2-
phenylpiperidine, 29  and biomimetic NADH models. 30
27
 Relatively few methods for the 
synthesis of 6-arylpiperidine-2,4-diones have been reported in the literature. An important 
method is the coupling of β-aryl-β-amino esters with alkyl malonates, followed by 
Dieckmann condensation, hydrolysis and decarboxylation.  Alternatively, β-aryl-β-amino 
acid derivatives can be reacted with metal enolates of alkyl acetates or with Meldrum’s acid in 
the presence of pyridine to afford the corresponding δ-amino-β-keto esters which are 
subsequently cyclized under basic conditions to give 6-arylpiperidine-2,4-diones.29, 31 
Analogously, a number of 6-arylpiperidine-2,4-diones were obtained by reaction of chiral N-
sulfinyl imines with lithium or TMS dienolates of 2,2,6-trimethyl-1,3-dioxin-4-one. 32  An 
early efficient preparation of 1-tert-butyl-6-phenylpiperidine-2,4-dione involved the addition 
of N-benzylidene-tert-butylamine to diketene.33 1-Methyl-6-phenylpiperidine-2,4-dione was 
synthesized in moderate yield through 1,3-dipolar cycloaddition of the appropriate nitrone 
with methyl 2-chlorobut-3-enoate and subsequent hydrogenolysis of the intermediate 
isoxazolidine. 34  6-Arylpiperidine-2,4-diones are also accessible by acid hydrolysis of the 
cycloadducts obtained through aza-Diels-Alder reaction of 1,3-dimethoxy-1-
(trimethylsiloxy)butadiene (Brassard’s diene) with aromatic aldimines. 35 The formation of 
piperidine-2,4-diones 15 from 6-(iodomethyl)-1,3-oxazinan-2-ones 10 is believed to proceed 
via initial base-induced elimination of hydrogen iodide to give 6-methylene-1,3-oxazinan-2-
ones 16 followed by basic hydrolysis of the oxazinanone and intramolecular C-
carbamoylation of the formed enolate. The alkoxide-catalyzed rearrangement of isomeric 2-
alkylidene-1,3-oxazinan-6-ones to piperidine-2,4-diones has been described more than 40 
years ago. 36
Alternatively, the iodo substituent in 6-(iodomethyl)-1,3-oxazinan-2-ones 10c,d could be 
successfully substituted upon heating with sodium azide in DMSO which efficiently afforded 
the corresponding 6-(azidomethyl)-1,3-oxazinan-2-ones 17 (Scheme 5). The absence of a 
tethered leaving group in the C-6 substituent of 6-(azidomethyl)-1,3-oxazinan-2-ones 17, 
inhibiting base-induced elimination to 6-methylene-1,3-oxazinan-2-ones 16, allowed the 
solvolysis to 4-amino-4-aryl-1-azidobutan-2-ols 18 (81-90% yield) upon heating with sodium 
methoxide in methanol. Upon considering the aryl group as a carboxyl synthon,
 On the other hand, to the best of our knowledge, the rearrangement of 6-
alkylidene-1,3-oxazinan-2-ones to piperidine-2,4-diones has never been reported. 
37 the azido 
aminoalcohols 18 are of potential interest for further synthetic elaboration as they incorporate 
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the scaffold of the naturally occurring nonproteinogenic amino acids 4-hydroxyornithine and 
4-hydroxyarginine, 38  which are also constituents of the antibiotic cyclopeptide natural 
products biphenomycins,39 K-582 type antibiotics,40 and β-lactam antibiotic clavalanine.41
 
 
5 M NaOH (aq.)




10c (R1 = H, dr cis/trans 74:26)





15a (R1 = H, 86%)











17a (R1 = H, 81%, dr cis/trans 69:31)
17b (R1 = OMe, 85%, dr cis/trans 82:18)
R1
4 equiv 2 M NaOMe/MeOH
MeOH, ∆, 48 h
18a (R1 = H, 90%, dr syn/anti 72:28)







Similarly, the 6-(phenylselanylmethyl)-1,3-oxazinan-2-ones 10e,f were easily solvolyzed to 
the corresponding 4-amino-4-aryl-1-(phenylselanyl)butan-2-ols 19 (80-84% yield) (Scheme 




4 equiv 2 M NaOMe/MeOH




10e (R1 = H, dr cis/trans 46:54)
10f (R1 = MeO, dr cis/trans 44:56)
R1
19a (R1 = H, 84%, dr syn/anti 2:3)










In conclusion, an efficient synthesis of 6-functionalized 4-aryl-1,3-oxazinan-2-ones has been 
achieved based on electrophile-induced cyclocarbamation of benzyl N-(1-phenyl-3-
butenyl)carbamates. Most importantly, stereochemically pure cis-6-(bromomethyl)- and 6-
(iodomethyl)-4-phenyl-1,3-oxazinan-2-ones became accessible via cyclization of N-
unsubstituted Cbz-protected homoallylamines. On the other hand, the use of N-benzylated and 
in situ prepared N-silylated derivatives resulted in cyclocarbamation with trans-selectivity. 
Furthermore, the functionalized 1,3-oxazinan-2-ones could be elaborated towards biologically 






1H NMR spectra were recorded at 300 MHz with CDCl3 as solvent and tetramethylsilane as 
internal standard. 13C NMR spectra were recorded at 75MHz with CDCl3 as solvent. 
Dichloromethane was distilled over CaH2, DMF was distilled and kept over molecular sieves, 
methanol was dried by reaction with magnesium and distilled, while other solvents were used 
as received from the supplier. 
 
4.2. Synthetic procedures 
 
4.2.1. Synthesis of benzyl N-(1-phenyl-3-butenyl)carbamates 9. Benzyl N-(1-phenyl-3-
butenyl)carbamates 9 were prepared according to a literature procedure.23 
 
4.2.2. General procedure for the preparation of 4-aryl-1,3-oxazinan-2-ones 10. A solution 
of electrophile (1.22 mmol) (Br2, I2, PhSeBr) in freshly distilled dry dichloromethane (10 mL) 
was added dropwise in a period of 10 minutes to a stirred solution of benzyl N-(1-phenyl-3-
butenyl)carbamate 9 (1.0 mmol) in dichloromethane (20 mL) and the mixture was stirred at 
room temperature under nitrogen atmosphere for 16 – 24 hours. The reaction was quenched 
with 2 N aq. Na2SO3 (for reaction with Br2) or 2 N aq. Na2S2O3 (for reaction with I2) or brine 
(for reaction with PhSeBr). The mixture was extracted with dichloromethane, dried (MgSO4), 
filtered, evaporated under reduced pressure and the residue was crystallized from diethyl 
ether/hexane to afford 4-aryl-1,3-oxazinan-2-ones 10 as a mixture of cis- and trans-isomers. 
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4.2.3. cis-6-(Bromomethyl)-4-phenyl-1,3-oxazinan-2-one (10a). Isolated by column 
chromatography (diethyl ether). Amorphous white solid; mp: 183.0-185.0 °C; yield 42%. 1H 
NMR (300 MHz, CDCl3): δ = 1.86 (dt, 1H, J = 13.76 Hz, 11.56 Hz, 5-CH(H)), 2.47 (dddd, 
1H, J = 13.76 Hz, 4.40 Hz, 2.20 Hz, 1.65 Hz, 5-CH(H)), 3.46 (dd, 1H, J = 10.73 Hz, 6.88 Hz, 
CH(H)Br), 3.60 (dd, 1H, J = 10.73 Hz, 4.40 Hz, CH(H)Br), 4.57-4.65 (m, 1H, CHO), 4.63 
(dd, 1H, J = 11.70 Hz, 4.5 Hz, CHN), 5.32 (br s, 1H, NH), 7.31-7.45 (m, 5H, C6H5). 13C 
NMR (75 MHz, CDCl3): δ = 32.6, 35.3, 55.2, 75.8, 126.2, 129.0, 129.3, 140.2, 153.1. IR 
(ATR, cm-1): ν = 3225 (NH), 3121, 1696 (C=O). MS (ES, pos): m/z 270/272 (M+H+, 100). 
Anal. Calcd. for C11H12BrNO2: C, 48.91; H, 4.48; N, 5.19. Found: C, 48.87; H, 4.09; N, 5.06. 
 
4.2.4. trans-6-(Bromomethyl)-4-phenyl-1,3-oxazinan-2-one (10a). Isolated by column 
chromatography (diethyl ether). Amorphous white solid; mp: 157.1-159.1 °C; yield 14%. 1H 
NMR (300 MHz, CDCl3): δ = 2.17 (dddd, 1H, J = 13.9 Hz, 3.9 Hz, 3.0 Hz, 1.1 Hz, 5-CH(H)), 
2.40 (ddd, 1H, J = 14.0 Hz, 9.6 Hz, 5.8 Hz, 5-CH(H)), 3.48 (dd, 1H, J = 10.8 Hz, 6.7 Hz, 
CH(H)Br), 3.53 (dd, 1H, J = 10.8 Hz, 4.95 Hz, CH(H)Br), 4.42 (dddd, 1H, J = 9.5 Hz, 6.8 Hz, 
4.9 Hz, 2.8 Hz, CHO), 4.79 (dt, 1H, J = 5.5 Hz, 3.6 Hz, CHN), 5.48 (br s, 1H, NH), 7.29-7.45 
(m, 5H, C6H5). 13C NMR (75 MHz, CDCl3): δ = 32.3, 32.8, 52.3, 72.4, 125.9, 128.4, 129.2, 
141.2, 153.2. IR (ATR, cm-1): ν = 3243 (NH), 3124, 1690 (C=O). MS (ES, pos): m/z 270/272 
(M+H+, 100). Anal. Calcd. for C11H12BrNO2: C, 48.91; H, 4.48; N, 5.19. Found: C, 48.75; H, 
4.29; N, 5.39. 
 
4.2.5. cis-6-(Bromomethyl)-4-(4-methoxyphenyl)-1,3-oxazinan-2-one (10b). Isolated by 
column chromatography (diethyl ether). Colorless crystals; mp: 138.2-140.2 °C; yield 36%. 
1H NMR (300 MHz, CDCl3): δ = 1.83 (dt, 1H, J = 13.76 Hz, 11.56 Hz, 5-CH(H)), 2.41 (dddd, 
1H, J = 13.7 Hz, 4.2 Hz, 2. 0 Hz, 2.0 Hz, 5-CH(H)), 3.46 (dd, 1H, J = 10.73 Hz, 6.88 Hz, 
CH(H)Br), 3.59 (dd, 1H, J = 10.73 Hz, 4.40 Hz, CH(H)Br), 3.82 (s, 3H, CH3O), 4.54-4.62 (m, 
1H, CHO), 4.57 (dd, 1H, J = 11.56 Hz, 4.68 Hz, CHN), 5.46 (br s, 1H, NH), 6.89-6.94 (m, 2H, 
Ar-H), 7.23-7.28 (m, 2H, Ar-H). 13C NMR (75 MHz, CDCl3): δ = 32.6, 35.4, 54.7, 55.5, 75.8, 
114.6, 127.5, 132.1, 153.0, 160.0. IR (ATR, cm-1): ν = 3222 (NH), 3116, 1694 (C=O). MS 
(ES, M+H+, pos): m/z 300/302 (M+H+, 100). Anal. Calcd. for C12H14BrNO3: C, 48.02; H, 
4.70; N, 4.67. Found: C, 48.34; H, 4.36; N, 4.55. 
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4.2.6. trans-6-(Bromomethyl)-4-(4-methoxyphenyl)-1,3-oxazinan-2-one (10b). Isolated by 
column chromatography (diethyl ether). White crystals; mp: 146.0-148.0 °C; yield 11%. 1H 
NMR (300 MHz, CDCl3): δ = 2.13 (dddd, 1H, J = 14.0 Hz, 4.1 Hz, 3.0 Hz, 1.0 Hz, 5-CH(H)), 
2.36 (ddd, 1H, J = 13.9 Hz, 9.2 Hz, 5.6 Hz, 5-CH(H)), 3.48 (dd, 1H, J = 10.7 Hz, 6.9 Hz, 
CH(H)Br), 3.53 (dd, 1H, J = 10.7 Hz, 5.0 Hz, CH(H)Br), 3.82 (s, 3H, CH3O), 4.43 (dddd, 1H, 
J = 9.3 Hz, 6.8 Hz, 4.8 Hz, 2.7 Hz, CHO), 4.74 (m, 1H, CHN), 5.41 (br s, 1H, NH), 6.90-6.95 
(m, 2H, Ar-H), 7.21-7.24 (m, 2H, Ar-H). 13C NMR (75 MHz, CDCl3): δ = 32.2, 32.9, 51.8, 
55.5, 72.5, 114.5, 127.0, 133.1, 153.1, 159.6. IR (ATR, cm-1): ν = 3242 (NH), 3125, 1674 
(C=O). MS (ES, M+H+, pos): m/z 300/302 (M+H+, 100). Anal. Calcd. for C12H14BrNO3: C, 
48.02; H, 4.70; N, 4.67. Found: C, 48.40; H, 4.58; N, 4.58. 
 
4.2.7. cis-6-(Iodomethyl)-4-phenyl-1,3-oxazinan-2-one (10c). Isolated by column 
chromatography (diethyl ether). Colorless crystals; mp: 181.5-183.5 °C; yield 31%. 1H NMR 
(300 MHz, CDCl3): δ = 1.80 (dt, 1H, J = 13.76 Hz, 11.56 Hz, 5-CH(H)), 2.52 (ddt, 1H, J = 
13.76 Hz, 4.40 Hz, 1.93 Hz, 5-CH(H)), 3.29 (dd, 1H, J = 10.46 Hz, 7.43 Hz, CH(H)I), 3.43 
(dd, 1H, J = 10.46 Hz, 4.40 Hz, CH(H)I), 4.44 (dddd, 1H, J = 11.56 Hz, 7.02 Hz, 4.54 Hz, 2.3 
Hz, CHO), 4.63 (dd, 1H, J = 11.56 Hz, 4.68 Hz, CHN), 5.25 (br s, 1H, NH), 7.31-7.45 (m, 5H, 
C6H5). 13C NMR (75 MHz, CDCl3): δ = 5.5, 36.9, 55.2, 76.1, 126.2, 129.0, 129.3, 140.2, 
153.1. IR (ATR, cm-1): ν = 3223 (NH), 3121, 1696 (C=O). MS (ES, M+H+, pos): m/z 318 
(M+H+, 100). Anal. Calcd. for C11H12INO2: C, 41.66; H, 3.81; N, 4.42. Found: C, 41.52; H, 
3.45; N, 4.29. 
 
4.2.8. trans-6-(Iodomethyl)-4-phenyl-1,3-oxazinan-2-one (10c). Isolated by column 
chromatography (diethyl ether). Amorphous white solid; mp: 158.0-160.0 °C; yield 16%. 1H 
NMR (300 MHz, CDCl3): δ = 2.20 (dddd, 1H, J = 13.9 Hz, 4.0 Hz, 3.0 Hz, 1.0 Hz, 5-CH(H)), 
2.37 (ddd, 1H, J = 13.9 Hz, 9.2 Hz, 5.8 Hz, 5-CH(H)), 3.31 (dd, 1H, J = 10.73 Hz, 6.88 Hz, 
CH(H)I), 3.36 (dd, 1H, J = 10.73 Hz, 4.95 Hz, CH(H)I), 4.24 (dddd, 1H, J = 9.2 Hz, 7.1 Hz, 
5.0 Hz, 3.0 Hz, CHO), 4.76 (dt, 1H, J = 5.8 Hz, 3.6 Hz, CHN), 5.40 (br s, 1H, NH), 7.30-7.45 
(m, 5H, C6H5). 13C NMR (75 MHz, CDCl3): δ = 5.3, 34.4, 52.3, 72.7, 125.8, 128.4, 129.2, 
141.2, 153.2. IR (ATR, cm-1): ν = 3322 (NH), 1662 (C=O). MS (ES, M+H+, pos): m/z 318 
(M+H+, 100). Anal. Calcd. for C11H12INO2: C, 41.66; H, 3.81; N, 4.42. Found: C, 41.99; H, 
3.50; N, 4.33. 
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4.2.9. cis-6-(Iodomethyl)-4-(4-methoxyphenyl)-1,3-oxazinan-2-one (10d). Isolated by 
column chromatography (diethyl ether). White amorphous solid; mp: 159.4-161.4 °C; yield 
29%. 1H NMR (300 MHz, CDCl3): δ = 1.78 (dt, 1H, J = 14.03 Hz, 11.4 Hz, 5-CH(H)), 2.47 
(dddd, 1H, J = 13.76 Hz, 4.40 Hz, 2.0 Hz, 2.0 Hz, 5-CH(H)), 3.28 (dd, 1H, J = 10.59 Hz, 7.3 
Hz, CH(H)I), 3.43 (dd, 1H, J = 10.59 Hz, 4.5 Hz, CH(H)I), 3.82 (s, 3H, CH3O), 4.41 (dddd, 
1H, J = 11.28 Hz, 7.1 Hz, 4.6 Hz, 2.0 Hz, CHO), 4.57 (dd, 1H, J = 11.56 Hz, 4.40 Hz, CHN), 
5.31 (br s, 1H, NH), 6.89-6.94 (m, 2H, Ar-H), 7.23-7.28 (m, 2H, Ar-H). 13C NMR (75 MHz, 
CDCl3): δ = 5.7, 37.0, 54.6, 55.5, 76.0, 114.6, 127.5, 132.1, 153.3, 160.0. IR (ATR, cm-1): ν = 
3249 (NH), 3113, 1682 (C=O). MS (ES, M+H+, pos): m/z 348 (M+H+, 100). Anal. Calcd. for 
C12H14INO3: C, 41.52; H, 4.06; N, 4.03. Found: C, 41.56; H, 3.75; N, 4.01. 
 
4.2.10. trans-6-(Iodomethyl)-4-(4-methoxyphenyl)-1,3-oxazinan-2-one (10d). Isolated by 
column chromatography (diethyl ether). Amorphous white solid; mp: 157.2-159.2 °C; yield 
7%. 1H NMR (300 MHz, CDCl3): δ = 2.16 (dddd, 1H, J = 13.9 Hz, 4.2 Hz, 3.1 Hz, 0.9 Hz, 5-
CH(H)), 2.33 (ddd, 1H, J = 14.1 Hz, 8.9 Hz, 5.4 Hz, 5-CH(H)), 3.30 (dd, 1H, J = 10.73 Hz, 
7.15 Hz, CH(H)I), 3.36 (dd, 1H, J = 10.73 Hz, 4.95 Hz, CH(H)I), 3.82 (s, 3H, CH3O), 4.25 
(dddd, 1H, J = 9.1 Hz, 7.15 Hz, 4.95 Hz, 3.03 Hz, CHO), 4.69-4.73 (m, 1H, CHN), 5.54 (br s, 
1H, NH), 6.90-6.95 (m, 2H, Ar-H), 7.20-7.25 (m, 2H, Ar-H). 13C NMR (75 MHz, CDCl3): δ 
= 5.3, 34.5, 51.7, 55.5, 72.8, 114.5, 127.0, 133.1, 153.3, 159.6. IR (ATR, cm-1): ν = 3245 
(NH), 1664 (C=O). MS (ES, M+H+, pos): m/z 348 (M+H+, 100). Anal. Calcd. for C12H14INO3: 
C, 41.52; H, 4.06; N, 4.03. Found: C, 41.52; H, 3.70; N, 3.94. 
 
4.2.11. 4-Phenyl-6-(phenylselanylmethyl)-1,3-oxazinan-2-one (10e). Mixture of cis- and 
trans-isomer in a ratio 54/46, crystallized from diethyl ether/hexane. Amorphous white solid; 
mp: 127.4-129.4 °C; yield 79%. 1H NMR (300 MHz, CDCl3): δ = 1.75 (dt, 1H, J = 13.76 Hz, 
11.56 Hz, 5-CH(H)cis), 2.23-2.27 (m, 2H, 5-CH(H)trans), 2.51 (ddt, 1H, J = 13.76 Hz, 4.68 Hz, 
1.8 Hz, 5-CH(H)cis), 2.95 (dd, 1H, J = 12.80 Hz, 9.2 Hz, CH(H)Setrans), 2.98 (dd, 1H, J = 
12.93 Hz, 8.53 Hz, CH(H)Secis), 3.24 (dd, 1H, J = 12.93 Hz, 4.68 Hz, CH(H)Setrans), 3.33 (dd, 
1H, J = 12.93 Hz, 4.68 Hz, CH(H)Secis), 4.24-4.34 (m, 1H, CHOtrans), 4.50 (dddd, 1H, J = 
11.39 Hz, 8.6 Hz, 4.7 Hz, 2.0 Hz, CHOcis), 4.56 (dd, 1H, J = 11.42 Hz, 4.5 Hz, CHNcis), 4.64-
4.68 (m, 1H, CHNtrans), 5.32 (br s, 1H, NHcis), 5.60 (br s, 1H, NHtrans), 7.16-7.54 (m, 20H, Ar-
Hcis+trans). 13C NMR (75 MHz, CDCl3): δ = 30.6, 31.2, 33.4, 36.2, 52.6, 55.6, 73.5, 76.7 
(overlap with signal from CDCl3), 125.9, 126.2, 127.7, 127.9, 128.2, 128.8, 129.1, 129.3, 
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129.4, 129.5, 132.9, 134.0, 140.5, 141.5, 153.6, 153.7. IR (ATR, cm-1): ν = 3211 (NH), 3109, 
1686 (C=O). MS (ES, M+H+, pos): m/z 348/346 (M+H+, 100). Anal. Calcd. for C17H17NO2Se: 
C, 58.96; H, 4.95; N, 4.04. Found: C, 59.08; H, 4.56; N, 4.02. 
 
4.2.12. 4-(Methoxyphenyl)-6-(phenylselanylmethyl)-1,3-oxazinan-2-one (10f). Mixture of 
cis- and trans-isomer in a ratio 58/42, crystallized from diethyl ether/hexane. Amorphous 
white solid; mp: 93.1-95.1 °C; yield 85%. 1H NMR (300 MHz, CDCl3): δ = 1.74 (dt, 1H, J = 
13.76 Hz, 11.56 Hz, 5-CH(H)cis), 2.18-2.24 (m, 2H, 5-CH(H)trans), 2.47 (ddt, 1H, J = 13.76 Hz, 
4.40 Hz, 1.9 Hz, 5-CH(H)cis), 2.97 (dd, 1H, J = 12.80 Hz, 9.2 Hz, CH(H)Setrans), 2.98 (dd, 1H, 
J = 13.07 Hz, 8.4 Hz, CH(H)Secis), 3.26 (dd, 1H, J = 12.80 Hz, 4.5 Hz, CH(H)Setrans), 3.33 
(dd, 1H, J = 12.93 Hz, 4.68 Hz, CH(H)Secis), 3.81 (s, 3H, CH3Ocis), 3.82 (s, 3H, CH3Otrans), 
4.27-4.35 (m, 1H, CHOtrans), 4.44-4.53 (m, 1H, CHOcis), 4.51 (dd, 1H, J = 11.28 Hz, 4.3 Hz, 
CHNcis), 4.57-4.62 (m, 1H, CHNtrans), 5.15 (br s, 1H, NHcis), 5.38 (br s, 1H, NHtrans), 6.86-
7.54 (m, 18H, Ar-Hcis+trans). 13C NMR (75 MHz, CDCl3): δ = 30.6, 31.3, 33.4, 36.3, 51.9, 55.0, 
55.5, 73.6, 76.6, 114.3, 114.5, 127.1, 127.4, 127.6, 127.9, 128.6, 129.2, 129.4, 129.5, 132.4, 
132.8, 133.5, 133.9, 153.8, 153.9, 159.4, 159.9. IR (ATR, cm-1): ν = 3225 (NH), 3102, 1685 
(C=O). MS (ES, M+H+, pos): m/z 378/376 (M+H+, 100). Anal. Calcd. for C18H19NO3Se: C, 
57.45; H, 5.09; N, 3.72. Found: C, 57.46; H, 5.10; N, 3.72. 
 
4.2.13. Alternative procedure for the preparation of 4-aryl-1,3-oxazinan-2-ones 10. To a 
solution of homoallylamine 9 (1 mmol) in dichloromethane (20 mL) at 0 °C, TBDMSOTf 
(0.79 g, 3 mmol) and 2,6-lutidine (0.43 g, 4 mmol) was added. After stirring for 2 h at 0 °C, a 
solution of electrophile (2.44 mmol) in freshly distilled dry dichloromethane (10 mL) was 
added dropwise and the mixture was stirred at 0 °C under nitrogen atmosphere for 16 – 24 
hours. After typical workup, the mixture was purified by column chromatography (EtOAc) to 
afford 4-aryl-1,3-oxazinan-2-ones 10 as a mixture of trans- and cis-isomers. 
 
4.2.14. General procedure for the preparation of benzyl N-benzyl-N-(1-phenyl-3-
butenyl)carbamates 11. Benzyl bromide (60 mmol) was added to a solution of sodium 
iodide in acetone (80 mL). The mixture was stirred for 24 h in the dark at room temperature, 
quenched with water (50 mL) and extracted with Et2O (2 x 100 mL). The combined organic 
layers were dried (MgSO4), filtered and concentrated under reduced pressure to afford the 
pure benzyl iodide as a yellow oil. Sodium hydride (5.25 mmol) was washed three times with 
n-pentane after which DMF (10 mL) was added. The suspension was cooled to 0 °C and a 
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solution of homoallylamine 9 (3.5 mmol) dissolved in dry DMF (8 mL) was added. The 
mixture was stirred for 30 min and then transferred by cannula into a flask containing benzyl 
iodide (60 mmol) in dry DMF (15 mL). The mixture was stirred for additional 10 min at room 
temperature. The reaction was quenched with saturated aqueous NH4Cl solution and extracted 
with Et2O (2 x 30 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(hexane/Et2O 6:1) to give compounds 11. 
 
4.2.15. Benzyl N-benzyl-N-(1-phenyl-3-butenyl)carbamate (11a). Colourless oil; yield 
70%. 1H NMR (300 MHz, CDCl3, recorded at 50 °C): δ = 2.67 (t, 2H, J = 7.2 Hz, CH2CH=), 
4.19 (d, 1H, J = 15.69 Hz, NCH(H)), 4.42 (d, 1H, J = 15.69 Hz, NCH(H)), 4.93-4.99 (m, 2H, 
=CH2), 5.17 (s, 2H, OCH2), 5.32-5.43 (m, 1H, CHN), 5.60-5.73 (m, 1H, CH=), 7.00-7.33 (m, 
15H, Ar-H). IR (ATR, cm-1): ν = 1691 (C=O). MS (ES, pos): m/z 372 (M+H+, 100). 
Purity >94% as determined by reverse phase HPLC analysis (integration at 220 nm). 
 
4.2.16. Benzyl N-benzyl-N-(1-(4-methoxyphenyl)-3-butenyl)carbamate (11b). Colourless 
oil; yield 65%. 1H NMR (300 MHz, CDCl3, recorded at 50 °C): δ = 2.63 (t, 2H, J = 7.2 Hz, 
CH2CH=), 3.78 (s, 3H, CH3O), 4.16 (d, 1H, J = 15.96 Hz, NCH(H)), 4.40 (d, 1H, J = 15.69 
Hz, NCH(H)), 4.92-4.98 (m, 2H, =CH2), 5.17 (s, 2H, OCH2), 5.28-5.38 (m, 1H, CHN), 5.59-
5.72 (m, 1H, CH=), 6.77-6.82 (m, 2H, Ar-H), 7.00-7.32 (m, 12H, Ar-H). 13C NMR (75 MHz, 
CDCl3): δ = 36.1, 47.2 (broad), 55.4, 58.9, 67.4, 113.8, 117.5, 126.9, 127.3 (broad), 128.0 
(broad), 128.2, 128.5, 129.6, 131.4, 135.0, 136.7, 139.1, 156.9, 159.1. IR (ATR, cm-1): ν = 
1691 (C=O), 1610. MS (ES, pos): m/z 402 (M+H+, 48), 294 (90), 250 (100), 204 (95), 161 
(72). Purity >92% as determined by reverse phase HPLC analysis (integration at 220 nm). 
 
4.2.17. General procedure for the preparation of 4-aryl-3-benzyl-1,3-oxazinan-2-ones 12. 
A solution of electrophile (1.22 mmol) in freshly distilled dry dichloromethane (10 mL) was 
added dropwise in a period of 10 minutes to a stirred solution of benzyl N-benzyl-N-(1-
phenyl-3-butenyl)carbamate 11 (1.0 mmol) in dichloromethane (20 mL) and the mixture was 
stirred at room temperature under nitrogen atmosphere for 18 – 40 hours. After typical 
workup, the mixture was purified by column chromatography (EtOAc) to afford 4-aryl-3-
benzyl-1,3-oxazinan-2-ones 12 as a mixture of trans- and cis-isomers. 
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4.2.18. trans-3-Benzyl-6-(bromomethyl)-4-phenyl-1,3-oxazinan-2-one (12a). Isolated by 
column chromatography (EtOAc) and crystallization from dichloromethane/hexane. 
Amorphous white solid; mp: 131.7-133.7 °C; yield 86%. 1H NMR (300 MHz, CDCl3): δ = 
2.13 (ddd, 1H, J = 13.76 Hz, 2.75 Hz, 2.75 Hz, 5-CH(H)), 2.20 (ddd, 1H, J = 13.69 Hz, 10.9 
Hz, 5.6 Hz, 5-CH(H)), 3.42 (dd, 1H, J = 10.87 Hz, 6.2 Hz, CH(H)Br), 3.47 (dd, 1H, J = 10.87 
Hz, 4.5 Hz, CH(H)Br), 3.66 (d, 1H, J = 15.13 Hz, NCH(H)), 4.36-4.44 (m, 1H, CHO), 4.53 
(dd, 1H, J = 5.50 Hz, 2.48 Hz, CHN), 5.40 (d, 1H, J = 15.13 Hz, NCH(H)), 7.20-7.47 (m, 
10H, 2xC6H5). 13C NMR (75 MHz, CDCl3): δ = 33.0, 34.2, 50.6, 55.8, 71.6, 126.3, 128.0, 
128.3, 128.4, 128.9, 129.4, 136.5, 139.5, 153.6. IR (ATR, cm-1): ν = 1674 (C=O). MS (ES, 
pos): m/z 360/362 (M+H+, 100). Anal. Calcd. for C18H18BrNO2: C, 60.01; H, 5.04; N, 3.89. 
Found: C, 59.94; H, 4.64; N, 3.83. 
 
4.2.19. trans-3-Benzyl-6-(bromomethyl)-4-(4-methoxyphenyl)-1,3-oxazinan-2-one (12b). 
Isolated together with the cis-isomer 12b as 85:15 mixture by column chromatography 
(EtOAc). Viscous colourless oil; yield 85%. 1H NMR (300 MHz, CDCl3): δ = 2.09 (ddd, 1H, 
J = 13.7 Hz, 2.8 Hz, 2.8 Hz, 5-CH(H)), 2.16 (ddd, 1H, J = 13.7 Hz, 11.01 Hz, 5.6 Hz, 5-
CH(H)), 3.41 (dd, 1H, J = 10.8 Hz, 6.33 Hz, CH(H)Br), 3.47 (dd, 1H, J = 10.8 Hz, 4.68 Hz, 
CH(H)Br), 3.84 (s, 3H, CH3O), 3.65 (d, 1H, J = 15.13 Hz, NCH(H)), 4.37-4.45 (m, 1H, CHO), 
4.47 (dd, 1H, J = 5.23 Hz, 2.20 Hz, CHN), 5.37 (d, 1H, J = 15.13 Hz, NCH(H)), 6.92-7.37 (m, 
9H, Ar-H). 13C NMR (75 MHz, CDCl3): δ = 33.0, 34.3, 50.5, 55.3, 55.5, 71.7, 114.7, 127.5, 
127.9, 128.3, 128.9, 131.3, 136.5, 153.6, 159.6. IR (ATR, cm-1): ν = 1689 (C=O).  MS (ES, 
pos): m/z 390/392 (M+H+, 100). Purity >90% as determined by reverse phase HPLC analysis 
(integration at 220 nm). 
 
4.2.20. trans-3-Benzyl-6-(iodomethyl)-4-phenyl-1,3-oxazinan-2-one (12c). Isolated 
together with the cis-isomer 12c as 94:6 mixture by column chromatography (EtOAc) and 
crystallization from dichloromethane/hexane. Amorphous white solid; mp: 135.8-137.8 °C; 
yield 85%. 1H NMR (300 MHz, CDCl3): δ = 2.07-2.21 (m, 2H, 5-CH2), 3.23 (dd, 1H, J = 
10.59 Hz, 6.5 Hz, CH(H)I), 3.30 (dd, 1H, J = 10.59 Hz, 4.8 Hz, CH(H)I), 3.65 (d, 1H, J = 
15.13 Hz, NCH(H)), 4.14-4.22 (m, 1H, CHO), 4.51 (dd, 1H, J = 5.23 Hz, 2.75 Hz, CHN), 
5.40 (d, 1H, J = 15.13 Hz, NCH(H)), 7.18-7.46 (m, 10H, 2xC6H5). 13C NMR (75 MHz, 
CDCl3): δ = 6.3, 35.9, 50.5, 55.8, 71.8, 126.3, 127.9, 128.3, 128.4, 128.9, 129.4, 136.5, 139.6, 
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153.7. IR (ATR, cm-1): ν = 1677 (C=O). MS (ES, pos): m/z 408 (M+H+, 100). Anal. Calcd. 
for C18H18INO2: C, 53.09; H, 4.46; N, 3.44. Found: C, 52.73; H, 4.16; N, 3.62. 
 
4.2.21. trans-3-Benzyl-6-(iodomethyl)-4-(4-methoxyphenyl)-1,3-oxazinan-2-one (12d). 
Isolated together with the cis-isomer 12d as 91:9 mixture by column chromatography 
(EtOAc). Viscous yellow oil; yield 86%. 1H NMR (300 MHz, CDCl3): δ = 2.04-2.18 (m, 2H, 
5-CH2), 3.23 (dd, 1H, J = 10.46 Hz, 6.60 Hz, CH(H)I), 3.30 (dd, 1H, J = 10.46 Hz, 4.68 Hz, 
CH(H)I), 3.65 (d, 1H, J = 14.86 Hz, NCH(H)), 3.84 (s, 3H, CH3O), 4.15-4.23 (m, 1H, CHO), 
4.45 (dd, 1H, J = 4.95 Hz, 2.75 Hz, CHN), 5.38 (d, 1H, J = 15.13 Hz, NCH(H)), 6.92-7.37 (m, 
9H, Ar-H). 13C NMR (75 MHz, CDCl3): δ = 6.2, 36.0, 50.4, 55.3, 55.5, 71.9, 114.7, 127.4, 
127.9, 128.3, 128.9, 131.4, 136.6, 139.6, 153.6, 159.6. IR (ATR, cm-1): ν = 1687 (C=O). MS 
(ES, pos): m/z 438 (M+H+, 100). Anal. Calcd. for C19H20INO3: C, 52.19; H, 4.61; N, 3.20. 
Found: C, 52.53; H, 4.83; N, 3.44. 
 
4.2.22. 3-Benzyl-6-(phenylselanylmethyl)-4-phenyl-1,3-oxazinan-2-one (12e). Isolated as a 
66:33 trans/cis mixture by column chromatography (EtOAc). Viscous colourless oil; yield 
78%. 1H NMR (300 MHz, CDCl3): δ = 1.93 (dt, 1H, J = 14.03 Hz, 11.4 Hz, 5-CH(H)cis), 2.06 
(ddd, 1H, J = 13.76 Hz, 10.7 Hz, 5.8 Hz, 5-CH(H)trans), 2.27 (dt, 1H, J = 13.76 Hz, 2.48 Hz, 
5-CH(H)trans), 2.52 (ddd, 1H, J = 13.97 Hz, 5.9 Hz, 1.9 Hz, 5-CH(H)cis), 2.85 (dd, 1H, J = 
12.66 Hz, 8.81 Hz, CH(H)Setrans), 2.94 (dd, 1H, J = 12.93 Hz, 8.26 Hz, CH(H)Secis), 3.20 (dd, 
1H, J = 12.93 Hz, 4.40 Hz, CH(H)Setrans), 3.30 (dd, 1H, J = 12.93 Hz, 4.68 Hz, CH(H)Secis), 
3.54 (d, 1H, J = 15.13 Hz, NCH(H)cis), 3.60 (d, 1H, J = 15.13 Hz, NCH(H)trans), 4.22-4.38 (m, 
3H, CHOtrans+cis and CHNcis), 4.43 (dd, 1H, J = 5.78 Hz, 2.20 Hz, CHNtrans), 5.22 (d, 1H, J = 
14.86 Hz, NCH(H)cis), 5.36 (d, 1H, J = 15.13 Hz, NCH(H)trans), 7.03-7.51 (m, 30H, Ar-
Hcis+trans). 13C NMR (75 MHz, CDCl3): δ = 31.0, 31.1, 34.8, 38.0, 48.9, 50.4, 56.1, 58.6, 72.6, 
74.9, 126.4, 127.1, 127.6, 127.7, 127.8, 128.1, 128.3, 128.5, 128.6, 128.7, 128.8, 129.2, 129.3, 
129.5, 132.8, 134.1, 136.7, 136.8, 139.8, 139.9, 154.2, 154.8. IR (ATR, cm-1): ν = 1688 
(C=O). MS (ES, pos): m/z 436/438 (M+H+, 100). Anal. Calcd. for C24H23NO2Se: C, 66.05; H, 
5.31; N, 3.21. Found: C, 65.67; H, 5.58; N, 3.52. 
 
4.2.23. 3-Benzyl-4-(4-methoxyphenyl)-6-(phenylselanylmethyl)-1,3-oxazinan-2-one (12f). 
Isolated as a 50:50 trans/cis mixture by column chromatography (EtOAc). Viscous yellow oil; 
yield 82%. 1H NMR (300 MHz, CDCl3): δ = 1.92 (dt, 1H, J = 14.31 Hz, 11.5 Hz, 5-CH(H)cis), 
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2.02 (ddd, 1H, J = 13.62 Hz, 10.87 Hz, 5.6 Hz, 5-CH(H)trans), 2.22 (dt, 1H, J = 13.48 Hz, 2.48 
Hz, 5-CH(H)trans), 2.49 (ddd, 1H, J = 13.97 Hz, 6.1 Hz, 1.6 Hz, 5-CH(H)cis), 2.85 (dd, 1H, J = 
12.80 Hz, 8.9 Hz, CH(H)Setrans), 2.95 (dd, 1H, J = 12.93 Hz, 8.53 Hz, CH(H)Secis), 3.21 (dd, 
1H, J = 12.80 Hz, 4.5 Hz, CH(H)Setrans), 3.30 (dd, 1H, J = 12.93 Hz, 4.68 Hz, CH(H)Secis), 
3.55 (d, 1H, J = 15.13 Hz, NCH(H)cis), 3.60 (d, 1H, J = 15.13 Hz, NCH(H)trans), 3.83 (s, 3H, 
CH3Ocis), 3.85 (s, 3H, CH3Otrans), 4.21-4.34 (m, 3H, CHOtrans+cis and CHNcis), 4.37 (dd, 1H, J 
= 5.50 Hz, 2.75 Hz, CHNtrans), 5.19 (d, 1H, J = 15.13 Hz, NCH(H)cis), 5.34 (d, 1H, J = 15.13 
Hz, NCH(H)trans), 6.88-7.51 (m, 28H, Ar-Hcis+trans). 13C NMR (75 MHz, CDCl3): δ = 31.1 
(2C), 34.9, 38.0, 48.7, 50.3, 55.5 (2C), 55.6, 58.1, 72.6, 74.9, 114.5, 127.5, 127.6, 127.77, 
127.80, 128.3, 128.4, 128.7, 128.8, 129.3, 129.4, 131.6, 131.8, 132.8, 134.0, 136.8, 136.9, 
154.2, 154.8, 159.4, 159.7. IR (ATR, cm-1): ν = 1687 (C=O). MS (ES, pos): m/z 466/468 
(M+H+, 100). Anal. Calcd. for C25H25NO3Se: C, 64.38; H, 5.40; N, 3.00. Found: C, 64.70; H, 
5.69; N, 3.38. 
 
4.2.24. General procedure for the synthesis of 6-arylpiperidine-2,4-diones 15. To a 
solution of 4-aryl-6-(iodomethyl)-1,3-oxazinan-2-one 10 (1 mmol) in ethanol (25 mL) was 
added a 5 M aqueous solution of NaOH (25 mL) and the reaction mixture was stirred under 
reflux for 8 h. After  completion of the reaction, 5% HCl (aq.) was added and the reaction 
mixture was extracted with EtOAc and CH2Cl2. The combined organic layers were dried 
(MgSO4), filtered and concentrated under reduced pressure. The residue was crystallized from 
CH2Cl2/hexane to afford the pure 6-arylpiperidine-2,4-diones 15. 
 
4.2.25. 6-Phenylpiperidine-2,4-dione 15a. Amorphous yellowish solid; mp: 166.2-168.2 °C 
(lit. mp: 167-169 °C,27 166-168 °C for (R)-(+)-15a29, 164-168 °C32); yield 86%. 1H NMR 
(300 MHz, CDCl3): δ = 2.77 (dd, 1H, J = 16.0 Hz, 9.5 Hz, 5-CH(H)), 2.90 (dd, 1H, J = 16.0 
Hz, 4.40 Hz, 5-CH(H)), 3.39 (s, 2H, 3-CH2), 4.82 (ddd, 1H, J = 9.56 Hz, 4.5 Hz, 1.7 Hz, CH), 
6.25 (br s, 1H, NH), 7.31-7.47 (m, 5H, C6H5). 13C NMR (75 MHz, CDCl3): δ = 47.1, 47.3, 
52.9, 126.1, 128.9, 129.5, 139.3, 169.3, 202.4. IR (ATR, cm-1): ν = 3185 (NH), 1715 (C=O), 
1667 (NC=O). MS (ES, pos): m/z 190 (M+H+, 100). All spectroscopic data are in good 
correspondence with reported data.27,29,32 
 
4.2.26. 6-(4-Methoxyphenyl)piperidine-2,4-dione 15b. Amorphous white solid; mp: 172.4-
174.4 °C (lit. mp: 174-175 °C,27 171-172 °C43); yield 82%. 1H NMR (300 MHz, CDCl3): δ = 
 19 
2.74 (dd, 1H, J = 16.1 Hz, 9.36 Hz, 5-CH(H)), 2.85 (dd, 1H, J = 16.1 Hz, 4.40 Hz, 5-CH(H)), 
3.36 (s, 2H, 3-CH2), 3.82 (s, 3H, OCH3), 4.76 (dd, 1H, J = 9.36 Hz, 4.40 Hz, CH), 6.37 (br s, 
1H, NH), 6.93 (d, 2H, J = 8.81 Hz, Ar-H), 7.24 (d, 2H, J = 8.81 Hz, Ar-H). 13C NMR (75 
MHz, CDCl3): δ = 47.29, 47.33, 52.5, 55.5, 114.8, 127.4, 131.1, 160.0, 168.8, 202.5. IR (ATR, 
cm-1): ν = 3183 (NH), 1722 (C=O), 1665 (NC=O). MS (ES, pos): m/z 220 (M+H+, 100). 
 
4.2.27. General procedure for the preparation of 6-(azidomethyl)-1,3-oxazinan-2-ones 17. 
To a solution of 6-(iodomethyl)-1,3-oxazinan-2-one 10 (1 mmol) in DMSO (10 mL) was 
added sodium azide (2 mmol) and the reaction mixture was stirred at 80 °C for 14 h. After 
cooling, the reaction mixture was poured into H2O (30 mL) and extracted with EtOAc (3 x 30 
mL). The combined organic extracts were washed with brine. The organic layer was dried 
(MgSO4), filtered and evaporated under reduced pressure. Crystallisation of the residue from 
CH2Cl2/hexane afforded the pure 6-(azidomethyl)-1,3-oxazinan-2-ones 17 in 81-85% yield. 
 
4.2.28. 6-(Azidomethyl)-4-phenyl-1,3-oxazinan-2-one (17a). Mixture of cis- and trans-
isomer in a ratio 69/31. Amorphous purple solid; mp: 122.7-125.7 °C; yield 81%. 1H NMR 
(300 MHz, CDCl3): δ = 1.91 (dt, 1H, J = 13.76 Hz, 11.83 Hz, 5-CH(H)cis), 1.93-2.01 (m, 1H, 
5-CH(H)trans), 2.17-2.24 (m, 1H, 5-CH(H)cis), 2.36 (ddd, 1H, J = 13.8 Hz, 10.5 Hz, 5.8 Hz, 5-
CH(H)trans), 3.43 (dd, 1H, J = 13.07 Hz, 5.1 Hz, CH(H)N3,trans), 3.49-3.56 (m, 3H, 
CH(H)N3,trans and CH(H)N3,cis), 4.31-4.38 (m, 1H, CHOtrans), 4.55 (dddd, 1H, J = 11.70 Hz, 
5.0 Hz, 5.0 Hz, 2.1 Hz, CHOcis), 4.62 (dd, 1H, J = 11.56 Hz, 4.40 Hz, CHNcis), 4.82 (dt, 1H, J 
= 5.8 Hz, 3.0 Hz, CHNtrans), 5.26 (br s, 1H, NHcis), 5.58 (br s, 1H, NHtrans), 7.29-7.44 (m, 10H, 
2xC6H5). 13C NMR (75 MHz, CDCl3): δ = 31.7, 33.9, 52.4, 53.6, 53.8, 55.3, 71.9, 75.4, 125.8, 
126.0, 128.2, 128.9, 129.1, 129.3, 140.1, 141.3, 153.0, 153.2. IR (ATR, cm-1): ν = 3239 (NH), 
3123, 2098 (N3), 1696 (C=O). MS (ES, pos): m/z 233 (M+H+, 100). Purity >96% as 
determined by reverse phase HPLC analysis (integration at 220 nm). 
 
4.2.29. 6-(Azidomethyl)-4-(4-methoxyphenyl)-1,3-oxazinan-2-one (17b). Mixture of cis- 
and trans-isomer in a ratio 82/18. Amorphous grey solid; mp: 158.1-160.1 °C; yield 85%. 1H 
NMR (300 MHz, CDCl3): δ = 1.88 (dt, 1H, J = 13.76 Hz, 11.7 Hz, 5-CH(H)cis), 1.89-1.96 (m, 
1H, 5-CH(H)trans), 2.11-2.19 (m, 1H, 5-CH(H)cis), 2.30 (ddd, 1H, J = 13.9 Hz, 10.3 Hz, 5.9 Hz, 
5-CH(H)trans), 3.43 (dd, 1H, J = 12.93 Hz, 5.23 Hz, CH(H)N3,trans), 3.47-3.53 (m, 1H, 
CH(H)N3,trans), 3.53 (dd, 1H, J = 13.21 Hz, 4.95 Hz, CH(H)N3,cis), 3.54 (dd, 1H, J = 13.21 Hz, 
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4.95 Hz, CH(H)N3,cis), 3.81 (s, 3H, CH3Otrans), 3.82 (s, 3H, CH3Ocis), 4.33 (dddd, 1H, J = 
10.25 Hz, 5.0 Hz, 5.0 Hz, 2.7 Hz, CHOtrans), 4.48-4.56 (m, 1H, CHOcis), 4.56 (dd, 1H, J = 
11.42 Hz, 4.5 Hz, CHNcis), 4.76 (dt, 1H, J = 5.5 Hz, 3.2 Hz, CHNtrans), 5.47 (br s, 1H, NHcis), 
5.94 (br s, 1H, NHtrans), 6.89-6.94 (m, 4H, Ar-H), 7.20-7.27 (m, 4H, Ar-H). 13C NMR (75 
MHz, CDCl3): δ = 31.8, 33.9, 51.8, 53.6, 53.8, 54.7, 55.4, 71.9, 75.4, 114.3, 114.5, 126.9, 
127.4, 132.0, 133.2, 153.0, 153.3, 159.4, 159.9. IR (ATR, cm-1): ν = 3325 (NH), 2138 (N3), 
2110 (N3), 1711 (C=O). MS (ES, pos): m/z 263 (M+H+, 100). Purity >95% as determined by 
reverse phase HPLC analysis (integration at 220 nm). 
 
4.2.30. General procedure for the synthesis of 4-amino-4-aryl-1-azidobutan-2-ols 18. To 
a solution of 6-(azidomethyl)-1,3-oxazinan-2-one 17 (1 mmol) in MeOH (10 mL) was added 
2 M NaOMe in MeOH (2 mL, 4 mmol). The solution was stirred under reflux for 48 h, 
evaporated under reduced pressure, diluted with CH2Cl2 (50 mL) and H2O (50 mL). The 
aqueous layer was extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were 
dried (MgSO4), filtered and evaporated under reduced pressure. Purification by column 
chromatography with EtOAc afforded the pure aminoalcohol 18 in 81-90% yield. 
 
4.2.31. 4-Amino-1-azido-4-phenylbutan-2-ol 18a. Mixture of syn- and anti-isomer in a ratio 
78/22. Amorphous yellowish solid; mp: 52.5-55.2 °C; yield 90%. 1H NMR (300 MHz, 
CDCl3): δ = 1.73-1.84 (m, 3H, 3-CH(H)syn and 3-CH(H)anti), 1.93 (ddd, 1H, J = 14.31 Hz, 
8.67 Hz, 3.7 Hz, 3-CH(H)anti), 3.22-3.34 (m, 4H, CH(H)N3,anti+syn), 3.91 (ddt, 1H, J = 8.53 Hz, 
5.4 Hz, 3.03 Hz, CHOanti), 4.02-4.07 (m, 1H, CHNsyn), 4.10-4.17 (m, 1H, CHOsyn), 4.46 (dd, 
1H, J = 6.60 Hz, 3.58 Hz, CHNanti), 7.23-7.40 (m, 10H, Ar-Hanti+syn). 13C NMR (75 MHz, 
CDCl3): δ = 40.3, 40.6, 53.7, 56.7, 56.9 (2C), 68.7, 71.1, 125.4, 125.9, 127.51, 127.54, 128.9, 
129.1, 144.2, 146.4. IR (ATR, cm-1): ν = 3356 (OH), 3288 (NH), 2095 (N3). MS (ES, pos): 
m/z 207 (M+H+, 100). Purity >92% as determined by reverse phase HPLC analysis 
(integration at 220 nm). 
 
4.2.32. syn-4-Amino-1-azido-4-(4-methoxyphenyl)butan-2-ol 18b. Isolated in a syn/anti 
ratio >90/10. Amorphous yellowish solid; mp: 63.1-65.8 °C; yield 81%. 1H NMR (300 MHz, 
CDCl3): δ = 1.72-1.85 (m, 2H, 3-CH(H)), 3.25 (dd, 1H, J = 12.38 Hz, 5.78 Hz, CH(H)N3), 
3.30 (dd, 1H, J = 12.66 Hz, 5.0 Hz, CH(H)N3), 3.81 (s, 3H, CH3O), 3.98-4.03 (m, 1H, CHN), 
4.07-4.15 (m, 1H, CHO), 4.46 (dd, 1H, J = 6.60 Hz, 3.58 Hz, CHNanti), 6.87-6.90 (m, 2H, Ar-
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H), 7.15-7.19 (m, 2H, Ar-H). 13C NMR (75 MHz, CDCl3): δ = 40.5, 55.3, 56.1, 56.8, 71.9, 
114.2, 126.4, 138.6, 158.8. IR (ATR, cm-1): ν = 3366 (OH), 3293 (NH), 2097 (N3). MS (ES, 
pos): m/z no M+H+, 192 (100). Purity >87% as determined by reverse phase HPLC analysis 
(integration at 220 nm). 
 
4.2.33. General procedure for the synthesis of 4-amino-4-aryl-1-(phenylselanyl)butan-2-
ols 19. To a solution of 6-(phenylselanylmethyl)-1,3-oxazinan-2-one 10 (1 mmol) in MeOH 
(10 mL) was added 2 M NaOMe in MeOH (2 mL, 4 mmol). The solution was stirred under 
reflux for 36-40 h, evaporated under reduced pressure, diluted with CH2Cl2 (50 mL) and H2O 
(50 mL). The aqueous layer was extracted with CH2Cl2 (2 x 50 mL). The combined organic 
layers were dried (MgSO4), filtered and evaporated under reduced pressure. Purification by 
column chromatography with EtOAc afforded the pure aminoalcohol 19 in 80-84% yield. 
 
4.2.34. 4-Amino-4-phenyl-1-(phenylselanyl)butan-2-ol 19a. Mixture of syn- and anti-
isomer in a ratio 2/3. Amorphous white solid; mp: 95.7-97.7 °C; yield 84%. 1H NMR (300 
MHz, CDCl3): δ = 1.75 (dt, 1H, J = 14.03 Hz, 10.46 Hz, 3-CH(H)anti), 1.90-2.02 (m, 3H, 3-
CH(H)syn and 3-CH(H)anti), 2.82-3.33 (m, 8H, CH(H)Seanti+syn and NH2,anti+syn), 3.87-3.95 (m, 
1H, CHOsyn), 4.01 (dd, 1H, J = 10.73 Hz, 2.75 Hz, CHNanti), 4.04-4.12 (m, 1H, CHOanti), 4.33 
(t, 1H, J = 5.6 Hz, CHNsyn), 7.19-7.53 (m, 20H, Ar-Hanti+syn). 13C NMR (75 MHz, CDCl3): δ = 
35.7, 35.9, 43.0, 43.3, 53.4, 56.7, 68.4, 71.9, 125.6, 126.0, 126.9, 127.1, 127.3, 127.4, 128.8, 
129.0, 129.2, 130.0, 130.6, 132.5, 133.0, 145.1, 146.6. IR (ATR, cm-1): ν = 3342 (OH), 3273 
(NH). MS (ES, M+H+, pos): m/z 322/320 (M+H+, 100). Anal. Calcd. for C16H19NOSe: C, 
60.00; H, 5.98; N, 4.37. Found: C, 60.36; H, 5.69; N, 4.37. 
 
4.2.35. 4-Amino-4-(methoxyphenyl)-1-(phenylselanyl)butan-2-ol 19b. Mixture of syn- and 
anti-isomer in a ratio 49/51. Amorphous white solid; mp: 101.3-103.3 °C; yield 80%. 1H 
NMR (300 MHz, CDCl3): δ = 1.73 (dt, 1H, J = 14.03 Hz, 10.46 Hz, 3-CH(H)anti), 1.88-1.99 
(m, 3H, 3-CH(H)syn and 3-CH(H)anti), 2.95-3.11 (m, 4H, CH(H)Seanti+syn), 3.80 (s, 3H, 
CH3Osyn), 3.81 (s, 3H, CH3Oanti), 3.86-3.947 (m, 1H, CHOsyn), 3.97 (dd, 1H, J = 10.73 Hz, 
3.03 Hz, CHNanti), 4.03-4.11 (m, 1H, CHOanti), 4.30 (t, 1H, J = 5.6 Hz, CHNsyn), 6.85-7.53 (m, 
18H, Ar-Hanti+syn). 13C NMR (75 MHz, CDCl3): δ = 35.7, 35.9, 43.0, 43.4, 52.9, 55.4, 56.1, 
68.4, 71.8, 114.1, 114.2, 126.6, 126.9, 127.0, 127.1, 129.2, 130.0, 130.6, 132.5, 133.0, 137.1, 
139.0, 158.8. IR (ATR, cm-1): ν = 3338 (OH), 3259 (NH). MS (ES, M+H+, pos): m/z 333/335 
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(100). Anal. Calcd. for C17H21NO2Se: C, 58.29; H, 6.04; N, 4.00. Found: C, 57.97; H, 6.36; N, 
4.15. 
 
4.3. Crystal Data. Compound cis-10b was crystallized (colorless blocks) by slow evaporation 
from a diethyl ether solution at room temperature. C12H14BrNO3, Mr = 300.15, monoclinic, 
space group P21/c, a = 14.6488(9) Å , b = 6.2920(4) Å , c = 15.2272(7) Å ,U = 1275.36(13) 
Å3, Z = 4, T = 173(2) K, 9756 reflections measured, 2290 unique (Rint = 0.057). The final 
wR(F2) was 0.088 (all data). Crystallographic data for the structural analysis of compound cis-
10b have been deposited at the Cambridge Crystallographic Data Centre. The CCDC 767171 
has been assigned to the compound cis-10b. Copies of the information may be obtained free 
of charge from The Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44-
1223-336033; e-mail: deposit@ccdc.cam.ac.uk or www: http://www.ccdc.cam.ac.uk). 
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